Eagle Pharmaceuticals Inc
NASDAQ:EGRX
Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 102 full-time employees. The company went IPO on 2014-02-12. The firm's commercialized products include Ryanodex, Bendeka, Belrapzo, Treakisym, and Pemfexy. Ryanodex is used for malignant hyperthermia. EP-4104 Ryanodex (dantrolene sodium) is used for the treatment of organophosphate exposure. Belrapzo, Bendeka and Treakisym are used for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Pemfexy is an IV-administered cancer agent indicated for locally advanced or metastatic non-small cell lung cancer and mesothelioma. Its oncology and CNS/metabolic critical care pipeline includes product candidates that addresses underserved therapeutic areas across multiple disease states. Its vasopressin is an A-rated generic alternative to Vasostrict, which is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The company is engaged in clinical trials for CAL02, an approach to the treatment of severe bacterial pneumonia.
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 102 full-time employees. The company went IPO on 2014-02-12. The firm's commercialized products include Ryanodex, Bendeka, Belrapzo, Treakisym, and Pemfexy. Ryanodex is used for malignant hyperthermia. EP-4104 Ryanodex (dantrolene sodium) is used for the treatment of organophosphate exposure. Belrapzo, Bendeka and Treakisym are used for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Pemfexy is an IV-administered cancer agent indicated for locally advanced or metastatic non-small cell lung cancer and mesothelioma. Its oncology and CNS/metabolic critical care pipeline includes product candidates that addresses underserved therapeutic areas across multiple disease states. Its vasopressin is an A-rated generic alternative to Vasostrict, which is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The company is engaged in clinical trials for CAL02, an approach to the treatment of severe bacterial pneumonia.
Strong Quarter: Eagle delivered strong Q2 earnings and revenue, beating consensus for the fourth consecutive quarter.
Guidance Raised: Management raised full-year guidance and expects to end 2023 with over $100 million in net working capital.
Margin Improvement: Gross margin rose to 74%, and excluding amortization, reached 83%, driven by royalty expirations and strategic decisions.
Product Momentum: Hospital segment drugs BARHEMSYS and Byfavo posted ~30% sequential sales growth; oncology portfolio gross profit also increased.
Pipeline Progress: Key R&D programs, including EA-114 and CAL02, are advancing, with CAL02 receiving QIDP and Fast-Track designations.
Share Buybacks: The company resumed share repurchases in July, reflecting confidence in its outlook.
Strategic Focus: Eagle aims to leverage its expanded sales force and strong cash flow to add new products via R&D or acquisition.
